NGM·Healthcare·$166M·#263 / 520 in Healthcare
YDES YD Bio Limited
43SPECULATIVE
CATEGORY BREAKDOWN
GROWTH27
QUALITY22
STABILITY56
VALUATION0
GOVERNANCE98
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+16.9%
27
> 50% strong
Gross Margin
Revenue retained after direct costs
28.1%
37
> 50% strong
Cash Runway
Months of cash at current burn rate
11 months
35
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-0.2%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
324.8x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-866
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
81.0%
100
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+1.0%
94
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE YDES WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when YDES's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.